Impersonal research, traced to filings. An evidence-first read of whether Danaher's move up the value chain is real, well-stewarded, and still underappreciated — the same for every reader, from SEC EDGAR 10-K + 8-K filings. This is not personalized advice or a recommendation to any specific person. As of 24 Jul 2026. Disclosures.
How it scores
Seven dimensions, 0–5 — the baseline everyone has (28%) plus the revealed-behaviour Analysis Bridge (72%). The method →
Baseline
Analysis Bridge
The evidence, dimension by dimension
Execution (do-side)
4/5Strong operational execution against a cyclical backdrop: delivered the bioprocessing recovery (Biotech core +6.5%, high-single-digit bioprocessing consumables), returned total core sales to +2.0% growth, offset the <$300M tariff hit through DBS actions, and generated ~$6.4bn operating cash. Marked down (not 5) because Life Sciences remains in decline (core -1.5%, OPM -490bps) and consolidated OPM fell 130bps on repeated intangible/facility impairments — evidence some acquired assets are underperforming.
Say/do credibility
4/5Say/do reconciles well and honestly. The most important prior promise — that the 2023–24 bioprocessing de-stock was a cycle, not a structural break, and would recover — was delivered (Biotech core swung from -4.5% to +6.5%; management-flagged consumables recovery materialised). Prior full-year 'return to positive core growth' guidance also delivered, with a 'better-than-expected' Q4. Management's language stays appropriately hedged (2026 assumptions explicitly conditional on China policy and biotech funding). Held below 5 because Danaher reset guidance downward through 2023–24 as the destock ran longer than initially signalled, and the 2026 3–6% re-acceleration is still unproven (too_early); the credibility rests on a strong multi-decade DBS track record rather than pinpoint near-term forecasting.
Strategy — IP & partnerships
5/5Textbook up-the-value-chain strategy with a wide, IP/switching-cost moat. Portfolio deliberately migrated out of industrials/environmental (Fortive, Envista, Veralto spins) into higher-margin life-science tools, diagnostics and bioprocessing; ~recurring razor/razor-blade consumables & services model qualified into customers' regulated workflows; large intangible/IP base and continuous R&D; DBS as a repeatable operating and M&A engine. Structural gross-margin-up mix is explicit management strategy, not a byproduct.
Governance & stewardship
4/5Long-tenured, disciplined capital allocator with clean investment-grade financial governance (~$6.4bn operating cash, $5.0bn undrawn revolver, conservative leverage, transparent non-GAAP reconciliations and core-sales definitions, executive incentives tied to core growth). No adverse governance events surfaced in the 8-K stream (routine Item 5.02 changes; no restatement/enforcement). Not a 5 given family/founder (Rales)-influenced legacy and reliance on non-GAAP core measures in guidance; repeated impairments also warrant modest caution on acquisition governance.
Margins over the cycle
Operating margin and return on capital across the last decade of SEC filings. A structural climb up the value chain holds its gains through the down-cycle; a commodity name gives them back. Structural vs cyclical →
From SEC EDGAR XBRL.
The say/do credibility ledger
What management promised, versus what the filings show they delivered — the single largest weight in the read.
| Promise | When | Status | What the filings show |
|---|---|---|---|
| Bioprocessing would recover after the 2023–24 customer inventory de-stocking, with consumables returning to growth on monoclonal-antibody demand. | 2024 earnings calls / MD&A (recovery framed for 2025) | Delivered | Biotechnology core sales grew +6.5% in 2025 (vs -4.5% in 2024), led by high-single-digit core growth in bioprocessing driven by improved consumables demand from large pharma and CDMO customers; segment operating margin rose 70bps to 25.6%. Reverses the prior de-stocking decline. 10-K FY2025 MD&A — Biotechnology segment; Q4 2025 earnings release (CEO: 'continued strength in our bioprocessing business') |
| Return the company to positive total core-sales growth in 2025 after the 2024 decline. | FY2024 guidance (early 2025) | Delivered | Total core sales +2.0% in 2025 vs -1.5% in 2024; total sales +3.0%. Q4 characterised by management as 'better-than-expected performance across our portfolio' and exceeding the Q4 margin target. 10-K FY2025 MD&A (Sales/Core Sales Growth table); Q4 2025 earnings release (CEO Rainer Blair) |
| Re-accelerate toward higher core growth in 2026 (3–6%) as Diagnostics moves past China policy headwinds and Life Sciences end-markets modestly improve. | Q4 2025 earnings release (2026-01-28) | Too early | Company initiated FY2026 guidance of 3%–6% non-GAAP core revenue growth and adjusted EPS $8.35–$8.50; MD&A assumes Diagnostics growth improves past peak China policy headwinds and Life Sciences modestly improves. Not yet delivered; Q1 2026 only guided to low-single digits. Q4 2025 earnings release 8-K (2026-01-28, Item 2.02) — FY2026 outlook; 10-K MD&A Overview (2026 segment assumptions) |
| Protect operating margins via DBS productivity even through soft end-markets and new tariffs. | MD&A / ongoing DBS framing | In progress | Underlying operating leverage held (Biotechnology +70bps; Diagnostics stable ~26.7%), and management 'largely offset' the <$300M 2025 tariff impact via footprint changes, surcharges and cost actions. However, reported consolidated OPM fell 130bps to 19.1% — driven mainly by intangible/facility impairments (-120bps), not core deterioration, and Life Sciences OPM collapsed 490bps (impairments + volume deleverage). 10-K FY2025 MD&A — Operating Profit Performance (consolidated and by segment); tariff discussion |
| Sharpen the portfolio to a pure life-science-tools/diagnostics/bioprocessing compounder via the Veralto spin. | 2023 (Veralto spin-off completed 2023-09-30) | Delivered | Veralto separated in 2023; FY2025 results reported on the streamlined three-segment continuing-operations base with ~59% international sales; the portfolio migration up the value chain is executed and reflected in disclosures. 10-K FY2025 MD&A (continuing operations; Veralto disposition, tax-opinion disclosure) |
Triangulation chain
A real migration lights up all five: stated → approved → funded → permitted → protected. An announced-only one stalls early.
Explicit up-chain strategy: portfolio concentrated post-Veralto spin (2023) and Fortive/Envista earlier into three higher-value, science-and-tech franchises (Biotechnology, Life Sciences, Diagnostics) 'united by the Danaher Business System', characterised by 'a high level of products and services that are sold on a recurring basis, primarily through a direct sales model.' MD&A frames long-term growth as developing 'innovative and differentiated new products and services with higher gross profit margins' and expanding in higher-growth market segments. (10-K FY2025 Item 1 (Business — General/DBS) and Item 7 MD&A Overview)
Board-level capital deployment executed and disclosed: completed the Veralto spin-off (2023) to focus the portfolio; ongoing acquisitions (e.g. Abcam plc, 2024) and a board-authorized share-repurchase program; capex of ~$1.16bn in 2025 directed at manufacturing/R&D/customer-facing capacity. (10-K FY2025 MD&A (Business Segments; Liquidity — additions to PP&E $1,156M; share repurchase programs, Note 18))
Self-funded from strong cash generation: net operating cash flow ~$6.4bn in 2025; investment-grade balance sheet with total debt ~$18.4bn against a $5.0bn undrawn revolving credit facility and large cash balances. Repurchased shares in 2024 and 2025 and pays a dividend; funds future buybacks from cash/debt issuance. (10-K FY2025 MD&A Liquidity and Capital Resources (operating cash ~$6.4bn; total debt ~$18.4bn; $5.0bn Credit Facility))
Regulated medical-device/diagnostics and biologics operations run with the required approvals; product launches such as the BioFire SpotFire GI Panel (rapid multiplex PCR) reach market, and the segments serve FDA-regulated clinical and bioprocessing customers. Regulatory approval is treated as a routine operating requirement, not a pending gate. (10-K FY2025 Item 1A (regulatory approvals); Q4 2025 earnings release (BioFire SpotFire GI Panel launch))
Durable moat: ~recurring razor/razor-blade consumables and services embedded in installed bioprocessing, molecular/clinical diagnostics and life-science instruments create high switching costs; large intangible/IP base (e.g. Biotechnology amortization ~12.4% of sales) and continuous R&D. Bioprocessing consumables are qualified into customers' regulated manufacturing workflows — a structural switching barrier. (10-K FY2025 Item 1 (recurring-revenue model / DBS); MD&A segment data (amortization of intangibles; consumables-led growth))
Catalysts
- Diagnostics assumed to move past peak China volume-based-procurement/reimbursement headwinds in 2026 · 2026 (guided 2026-01-28)
China diagnostics price/volume drag was a key 2025 core-sales headwind; lapping it supports the 3–6% FY2026 core-growth re-acceleration.
- Bioprocessing consumables recovery on monoclonal-antibody demand assumed to continue in 2026 · 2026
Bioprocessing is the highest-quality recurring franchise; continued consumables growth is the core of the structural (non-cyclical) up-chain thesis.
- New/threatened U.S. tariffs (IEEPA Supreme Court ruling Feb 2026; administration pursuing alternative authority) · 2025-2026
2025 tariff cost <$300M was largely offset by DBS actions; escalation or new statutory tariffs could pressure margins if not offset.
Sources
Bridged from SEC EDGAR 10-K + 8-K filings, latest 10-K filed 24 Feb 2026. Read the 10-K on SEC EDGAR → Provenance: agent-grounded-fulltext. Financials from SEC EDGAR XBRL; price from public market data.